Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Haidukon Feb 01, 2016 9:19am
170 Views
Post# 24511743

RE:RE:RE:New presentation out !

RE:RE:RE:New presentation out !
The answer might be… Taking a safety belt this time…
 
Merger or acquisition of a potential partner [might] creates unexpected delays” is the reason SBM initially (informally) invoked for the delays recorded with TFC-849 (initially supposed to be on the shelfs at the end of 2014, beginning of 2015)
 
In fact, for TFC-849, the problem was / is the 14 steps scaling up process (as compared to 3 steps for TFC-1067). To this, it should be added, the production costs of TFC-849 (1 USD production cost, as compared to TFC-1067 = 0.10 USD production cost) and the “Fiat” (TFC-849) compared to the “Ferrari” (TFC-1067)…
 
Hence, the “risk” mentioned about the “economic viability” of TFC-849 (as I recall, some comments were made in “The Interview” but I do not exactly remember them – someone to refresh my memory?). Anyhow, as already mentioned TFC-849, is a secondary target.
 
I presume the “merger and acquisition risk” regarding TFC-1067 is to be minimized, since this product is supposed to revolutionize the market (as sustained by SBM) and nobody will delay its market launch (15% of anticipated market share).

Bullboard Posts